Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-60Dendritic cell-based immunotherapy for prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-11-04 / Clin. Dev. Immunol. 2010;2010:517493RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2010-11-01 / Neoplasia 2010 Nov;12(11):906-14Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
/in Dendritic Cells, International Publications /von 2010-11-01 / Expert Opin Biol Ther 2010 Nov;10(11):1539-53[WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2240-2Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2010-10-28 / Blood 2011 Jan;117(2):393-402Personalized cancer vaccines
/in Dendritic Cells, International Publications /von 2010-10-28 / Expert Opin Biol Ther 2010 Dec;10(12):1637-47Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue
/in Dendritic Cells, International Publications /von 2010-10-27 / Vaccine 2010 Nov;28(51):8162-8Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2010-10-22 / BMC Cancer 2010 Oct;10:578
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution